Cardiac Troponin T and C-Reactive Protein for Predicting Prognosis, Coronary Atherosclerosis, and Cardiomyopathy in Patients Undergoing Long-term Hemodialysis
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
CONTEXT: Cardiac troponin T (cTnT) and C-reactive protein (CRP) are prognostic markers in acute coronary syndromes. However, for patients with end-stage renal disease (ESRD) the ability of combinations of these markers to predict outcomes, and their association with cardiac pathology, are unclear. OBJECTIVE: To investigate the association between levels of cTnT and CRP and long-term risk of cardiac pathology and death in patients with ESRD. DESIGN, SETTING, AND PARTICIPANTS: A prospective cohort study initiated February through June 1998 and enrolling 224 patients with ESRD from 5 hemodialysis centers in the Houston-Galveston region of Texas. Levels of cTnT and CRP were analyzed at study entry in patients without ischemic symptoms. MAIN OUTCOME MEASURES: All-cause mortality during a mean follow-up of 827 (range, 29-1327) days. Secondary outcomes in predefined substudies were coronary artery disease (CAD), decreased (< or =40%) left ventricular ejection fraction (LVEF), and presence of left ventricular hypertrophy (LVH). RESULTS: One hundred seventeen (52%) patients died during follow-up. For levels of cTnT and CRP, progressively higher levels predicted increased risk of death compared with the lowest quartile (for cTnT quartile 2: unadjusted hazard ratio [HR], 2.2; 95% confidence interval [CI], 1.2-4.1; quartile 3: HR, 2.7; 95% CI, 1.5-4.9; quartile 4: HR, 3.0; 95% CI, 1.6-5.3. For CRP quartile 2: HR, 0.9; 95% CI, 0.5-1.6; quartile 3: HR, 1.8; 95% CI, 1.1-3.1; quartile 4: HR, 1.8; 95% CI, 1.1-3.2). Both cTnT and CRP remained independent predictors of death after adjusting for a number of potential confounders. The combination of cTnT and CRP results provided prognostic information when patients were divided into groups at or above and below the biomarker medians (high cTnT/high CRP levels vs low cTnT/low CRP levels for risk of death: HR, 2.5; 95% CI, 1.5-4.0). Elevated levels of cTnT, but not CRP, were strongly associated with diffuse CAD (n = 67; 0%, 25%, 50%, and 62% prevalence of multivessel CAD across progressive cTnT quartiles, P<.001). An LVEF of 40% or less was identified in 4 (9%), 3 (8%), 10 (27%), and 7 (19%) of patients across cTnT quartiles (P =.07). No trend for cTnT levels was found among patients with LVH (P =.45); similarly, no trend for CRP was found among patients with LVH (P =.65) or an LVEF of 40% or less (P =.75). CONCLUSIONS: Among stable patients with ESRD, increasing levels of cTnT and CRP are associated with increased risk of death. Furthermore, higher levels of cTnT may identify patients with severe angiographic coronary disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1990) · Choice Reviews Online · doi:10.5860/choice.27-3338 · Cited by 35,305
Antman, E., Bassand, J.-P., Klein, W., Ohman, M., Lopez Sendon, J. L., Rydén, L., Simoons, M., & Tendera, M. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00804-4 · Cited by 4,821
Zhang, J., & Yu, K. F. (1998) · JAMA · doi:10.1001/jama.280.19.1690 · Cited by 4,138
Falk, E., Shah, P. K., & Fuster, V. (1995) · Circulation · doi:10.1161/01.cir.92.3.657 · Cited by 3,536
Clinical and echocardiographic disease in patients starting end-stage renal disease therapy
Foley, R. N., Parfrey, P. S., Harnett, J. D., Kent, G. M., Martin, C. J., Murray, D. C., & Barre, P. E. (1995) · Kidney International · doi:10.1038/ki.1995.22 · Cited by 1,299
Alpert, J. S., Thygesen, K. A., Antman, E. M., & Bassand, J. (2001) · Journal of the American College of Cardiology · Cited by 1,282
Lindahl, B., Toss, H., Siegbahn, A., Venge, P., & Wallentin, L. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431602 · Cited by 1,224
CASALE, P. N., DEVEREUX, R. B., MILNER, M., ZULLO, G., HARSHFIELD, G. A., PICKERING, T. G., & LARAGH, J. H. (1986) · Annals of Internal Medicine · doi:10.7326/0003-4819-105-2-173 · Cited by 1,078
C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients
Yeun, J. Y., Levine, R. A., Mantadilok, V., & Kaysen, G. A. (2000) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(00)70200-9 · Cited by 887
A standardized definition of ischemic cardiomyopathy for use in clinical research
Felker, G. M., Shaw, L. K., & O’Connor, C. M. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01738-7 · Cited by 724
Cited by
Authors/Task Force Members, Bassand, J.-P., Hamm, C. W., Ardissino, D., Boersma, E., Budaj, A., Fernandez-Aviles, F., Fox, K. A. A., Hasdai, D., Ohman, E. M., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm161 · Cited by 1,849
K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients
(2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.01.019 · Cited by 1,427
Herzog, C. A., Asinger, R. W., Berger, A. K., Charytan, D. M., Díez, J., Hart, R. G., Eckardt, K.-U., Kasiske, B. L., McCullough, P. A., Passman, R. S., et al. (2011) · Kidney International · doi:10.1038/ki.2011.223 · Cited by 922
Liu, Y., Coresh, J., Eustace, J. A., Longenecker, J. C., Jaar, B., Fink, N. E., Tracy, R. P., Powe, N. R., & Klag, M. J. (2004) · JAMA · doi:10.1001/jama.291.4.451 · Cited by 777
Chronic Kidney Disease and Coronary Artery Disease
Sarnak, M. J., Amann, K., Bangalore, S., Cavalcante, J. L., Charytan, D. M., Craig, J. C., Gill, J. S., Hlatky, M. A., Jardine, A. G., Landmesser, U., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.08.1017 · Cited by 741
Self-citationTroponin: the biomarker of choice for the detection of cardiac injury
Babuin, L., & Jaffe, A. S. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.050141 · Cited by 686
Biomarkers in Acute Cardiac Disease
Jaffe, A. S., Babuin, L., & Apple, F. S. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.02.056 · Cited by 639
C-Reactive Protein and the Prediction of Cardiovascular Events Among Those at Intermediate Risk
Ridker, P. M. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.052 · Cited by 623
Rapezzi, C., Biagini, E., & Branzi, A. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm498 · Cited by 595
Jeremias, A., & Gibson, C. M. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-9-200505030-00015 · Cited by 466
Menon, V., Greene, T., Wang, X., Pereira, A. A., Marcovina, S. M., Beck, G. J., Kusek, J. W., Collins, A. J., Levey, A. S., & Sarnak, M. J. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00455.x · Cited by 417
What Does Minor Elevation of C-Reactive Protein Signify?
Kushner, I., Rzewnicki, D., & Samols, D. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.06.057 · Cited by 372
Khan, N. A., Hemmelgarn, B. R., Tonelli, M., Thompson, C. R., & Levin, A. (2005) · Circulation · doi:10.1161/circulationaha.105.560128 · Cited by 351
Januzzi, J. L., Filippatos, G., Nieminen, M., & Gheorghiade, M. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs191 · Cited by 314
Sepsis-Associated Myocardial Dysfunction
Maeder, M., Fehr, T., Rickli, H., & Ammann, P. (2006) · Chest · doi:10.1378/chest.129.5.1349 · Cited by 310
Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease
(2010) · National Academies Press eBooks · doi:10.17226/12869 · Cited by 276
Impaired Renal Clearance Explains Elevated Troponin T Fragments in Hemodialysis Patients
Diris, J. H. C., Hackeng, C. M., Kooman, J. P., Pinto, Y. M., Hermens, W. T., & van Dieijen-Visser, M. P. (2004) · Circulation · doi:10.1161/01.cir.0000109483.45211.8f · Cited by 271
C-reactive protein and Hypertension
Hage, F. G. (2014) · Journal of Human Hypertension · doi:10.1038/jhh.2013.111 · Cited by 205
Metadata
- Authors
- deFilippi, C.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2003-07-16
- Volume
- 290
- Issue
- 3
- Pages
- 353
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2113079363
- Cited by
- 395
- References
- 27
- FWCI
- 16.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.